An interventional study of Change of normal concentration of povidone-iodine 5% to 1% in Dry Eye, sponsored by José Gerardo García Aguirre. Completed at 1 site in Mexico. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.
Sponsored by José Gerardo García Aguirre · Not applicable, Interventional, and Other
Objective and subjective comparison between the use of povidone-iodine 1% vs 5% as antiseptic in patients that need anti-VEGF intravitreal injection
Randomized, prospective clinical trial. One group was intervened with povidone-iodine at 5% and the other at 1% as antiseptic for anti-VEGF intravitreal injection. Each patient was evaluated before and after the injection of anti-VEGF for tear break up time, bulbar redness and ocular surface satining with fluorescein. Pain perception was also evaluated 15 minutes after the injection and 48 hours after.
1,325 studies on the registry are indexed under Dry Eye Syndromes; 193 are open to participants now.
This study's enrollment of 88 is above the median of 60 across 1,103 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →This is the only study on the registry with José Gerardo García Aguirre as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Povidone-iodine 1% was used as antiseptic during anti-VEGF intravitreal injection
Procedure: Change of normal concentration of povidone-iodine 5% to 1%
Povidone-iodine 5% was used as antiseptic during anti-VEGF intravitreal injection
Procedure: Change of normal concentration of povidone-iodine 5% to 1%
Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group.
Tear breaking rupture
NIKBUT was measured with Keratopgraph before and after intravitreal injection
Time frame: Change from baseline measured to 15 minutes post-injection
Bulbar redness
Bulbar redness was measured with Keratopgraph before and after intravitreal injection
Time frame: Change from baseline measured to 15 minutes post-injection
Oxford scale
Oxford scale was measured with fluorescein stain before and after intravitreal injection
Time frame: Change from baseline measured to 15 minutes post-injection
Pain analog scale
Pain using visual analog scale was measured 15 minutes and 48 hours after intravitreal injection
Time frame: Change from baseline measured to 15 minutes post-injection
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.